Stock LXEO LEXEO THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Lexeo Therapeutics, Inc.

Equities

LXEO

US52886X1072

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
16.63 USD +3.61% Intraday chart for Lexeo Therapeutics, Inc. +7.57% +23.92%
May. 09 Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 01 Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024. CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Lexeo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics to Participate in Upcoming Investor Conferences
Certain Options of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Certain Common Stock of Lexeo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-MAY-2024.
Lexeo Therapeutics Signs License Deal With Cornell for Potential Friedreich Ataxia Cardiomyopathy Drug
Lexeo Therapeutics, Inc. Announces Not to Stand for Reelection of Bernard Davitian as Director
Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
LEXEO THERAPEUTICS GRANTED FDA FAST TRACK DESIGNATION FOR LX2006, AN AAV-BASED GENE THERAPY CANDIDATE FOR THE TREATMENT OF FRIEDREICH'S ATAXIA CARDIOMYOPATHY
Lexeo Says AAV-Based Gene Therapy Candidate Gets US FDA's Fast Track Designation for Friedreich's Ataxia Cardiomyopathy
Lexeo Gets FDA Fast-Track Designation for LX2006 in Friedreich's Ataxia Cardiomyopathy
Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy
Lexeo Therapeutics, Inc. Announces the U.S. Food and Drug Administration Grants Fast Track Designation for LX2006, an Aav-Based Gene Therapy Candidate for the Treatment of Friedreich?s Ataxia Cardiomyopathy
Lexeo Therapeutics, Inc.(NasdaqGM:LXEO) added to S&P Global BMI Index
Lexeo Therapeutics Raises $95 Million Via Private Placement of Shares
Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Lexeo Therapeutics, Inc. announced that it has received $94.999833 million in funding from a group of investors
RBC Raises Price Target on Lexeo Therapeutics to $24 From $22, Cites 'Solid' Friedreich's Ataxia Data; Outperform, Speculative Risk Kept
Lexeo Therapeutics' Q4 Net Loss Narrows; Cash Runway Extended to 2027 -- Shares Jump Pre-Bell
LEXEO: ENTERED INTO COMMON STOCK PURCHASE AGREEMENT TO…
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LXEO Stock
  4. News Lexeo Therapeutics, Inc.
  5. Other languages